Effects of Specific Zidovudine Resistance Mutations and Substrate Structure on Nucleotide-Dependent Primer Unblocking by Human Immunodeficiency Virus Type 1 Reverse Transcriptase

Peter R. Meyer,† Suzanne E. Matsuura,† Adviye A. Tolun,† Ingrid Pfeifer,† Antero G. So,‡ John W. Mellors,§ and Walter A. Scott†*

Department of Biochemistry and Molecular Biology† and Department of Medicine,‡ University of Miami School of Medicine, Miami, Florida 33101, and Graduate School of Public Health and School of Medicine, University of Pittsburgh and the Veterans Affairs Medical Center, Pittsburgh, Pennsylvania 15261§

Received 6 September 2001/Returned for modification 4 December 2001/Accepted 4 February 2002

Nucleotide-dependent unblocking of chain-terminated DNA by human immunodeficiency virus type 1 reverse transcriptase (RT) is enhanced by the presence of mutations associated with 3'-azido-3'-deoxythymidine (AZT) resistance. The increase in unblocking activity was greater for mutant combinations associated with higher levels of in vitro AZT resistance. The difference between mutant and wild-type activity was further enhanced by introduction of a methyl group into the nucleotide substrate and was decreased for a nonaromatic substrate, suggesting that π–π interactions between RT and an aromatic structure may be facilitated by these mutations.

Many nucleoside analogues, including 3'-azido-3'-deoxythymidine (AZT), inhibit human immunodeficiency virus type 1 (HIV-1) replication. The phosphorylated forms of these compounds are incorporated during DNA synthesis by the HIV-1 reverse transcriptase (RT), resulting in chain termination and inhibition of viral replication (7, 9, 12, 22, 31, 32). Mutations at codons 41, 67, 70, 210, 215, and 219 in the HIV-1 RT gene result in resistance of HIV-1 to AZT in cell culture assays (29). Substitutions of phenylalanine and tyrosine for threonine at positions 41, 67, 70, 210, 215, and 219 in the HIV-1 RT gene inhibit viral replication (7, 9, 12, 22, 31, 32). Mutations at these positions are associated with 3'-azido-3'-deoxythymidine (AZT) resistance (1, 2, 18, 19). The biochemical contributions made by specific mutations in HIV-1 RT to its removal activity and the effects of changes in the structure of the nucleotide substrate on the wild-type (WT) and mutant activities. The mutations associated with AZT resistance identify a region of HIV-1 RT that may interact with the nucleoside moiety of a transition intermediate to facilitate the formation of the dinucleoside tetraphosphate.

Removal of AZTMP or ddAMP from blocked primer-templates by WT and mutant RT. Removal of AZTMP from a blocked primer-template was detected by the formation of unblocked primers that could be extended in a subsequent incubation as previously described (19–21). Removal of ddAMP was detected by the transfer of [32P]ddAMP to a labeled primer terminus to ATP to form [32P]Ap4ddA (19, 21). It has been shown that these assays give similar results for both AZTMP and ddAMP removal (19).

To measure AZTMP removal, DNA primer L33 (5'–CTAGTTTTTCTCCATCTAGACGATAACCAGA-3') was 5' labeled with [γ-32P]ATP and T4 polynucleotide kinase, annealed with DNA template WL50 (5'–GAGTCAGGCTGGAACACACATCCTGTTGTATCGTGCCTCTAGTTTTTCTCCATCTAGACGATAACCAGA-3') and chain terminated by extending with AZTTP and ddATP (19, 21) and chain terminated by extending with AZTTP and ddATP (19, 21).

Many nucleoside analogues, including 3'-azido-3'-deoxythymidine (AZT), inhibit human immunodeficiency virus type 1 (HIV-1) replication. The phosphorylated forms of these compounds are incorporated during DNA synthesis by the HIV-1 reverse transcriptase (RT), resulting in chain termination and inhibition of viral replication (7, 9, 12, 22, 31, 32). Mutations at codons 41, 67, 70, 210, 215, and 219 in the HIV-1 RT gene result in resistance of HIV-1 to AZT in cell culture assays (29). Substitutions of phenylalanine and tyrosine for threonine at positions 41, 67, 70, 210, 215, and 219 in the HIV-1 RT gene inhibit viral replication (7, 9, 12, 22, 31, 32). Mutations at these positions are associated with 3'-azido-3'-deoxythymidine (AZT) resistance (1, 2, 18, 19). The biochemical contributions made by specific mutations in HIV-1 RT to its removal activity and the effects of changes in the structure of the nucleotide substrate on the wild-type (WT) and mutant activities. The mutations associated with AZT resistance identify a region of HIV-1 RT that may interact with the nucleoside moiety of a transition intermediate to facilitate the formation of the dinucleoside tetraphosphate.

Removal of AZTMP or ddAMP from blocked primer-templates by WT and mutant RT. Removal of AZTMP from a blocked primer-template was detected by the formation of unblocked primers that could be extended in a subsequent incubation as previously described (19–21). Removal of ddAMP was detected by the transfer of [32P]ddAMP to a labeled primer terminus to ATP to form [32P]Ap4ddA (19, 21). It has been shown that these assays give similar results for both AZTMP and ddAMP removal (19).

To measure AZTMP removal, DNA primer L33 (5'–CTAGTTTTTCTCCATCTAGACGATAACCAGA-3') was 5' labeled with [γ-32P]ATP and T4 polynucleotide kinase, annealed with DNA template WL50 (5'–GAGTCAGGCTGGAACACACATCCTGTTGTATCGTGCCTCTAGTTTTTCTCCATCTAGACGATAACCAGA-3') and chain terminated by extending with AZTTP and ddATP (19, 21) and chain terminated by extending with AZTTP and ddATP (19, 21).
AZTMP from AZTMP-terminated primers, mutation at codon 215 alone had a small but significant effect, and the combination 41L/215Y resulted in a 3.3-fold increase in AZTMP removal over removal by WT RT. The removal of AZTMP by 67N/70R/215Y/219Q RT was 5-fold higher and that by 67N/70R/215Y/219Q RT was 10-fold higher than that by the WT. By contrast, with PPi as the substrate, the mutants had activities that were at most equal to that of WT RT (Fig. 1B and E).

**FIG. 1.** Effects of the AZT resistance mutations on removal of AZTMP from blocked primer-template. (A, C, and D) ATP-dependent rescue of AZTMP-terminated primer-template by WT and mutant RTs (21). (A) AZTMP-terminated 5'-32P-L33 primer–WL50 template (5 nM) was incubated with the indicated RT (200 nM) in the presence of 3.2 mM ATP for the indicated times at 37°C. The RT was inactivated by heat treatment, and the unblocked primer was extended by incubation with exonuclease-free Klenow fragment of *E. coli* DNA polymerase I and all four dNTPs. Products were fractionated on a 20% denaturing polyacrylamide gel. Positions for unextended primer (primer) and for products formed after elongation to the end of the template (ext. primer) are shown on the left. (B) Rescue experiments were performed as for panel A, but with 50 μM PPi, instead of ATP. (C) Radioactivity in products longer than 34 nucleotides (rescued primers) from experiments shown in panel A was quantitated by phosphorimaging, expressed as a percentage of total radioactivity in the lane, and plotted against time. In panels C, D, and E, the lines represent the best fit to the Michaelis-Menten equation using SigmaPlot 4.0. (D) Rate of rescue of AZTMP-terminated primer-template as a function of the ATP concentration. Rescue experiments were performed as described for panel A, except that the ATP concentration varied from 0.2 to 6.4 mM, and the incubation times varied from 2 to 90 min, depending on the RT, to allow a maximum of 35% rescue. (E) Radioactivity in products longer than 34 nucleotides (rescued primers) from experiments shown in panel B was quantitated by phosphorimaging, expressed as percentage of total radioactivity in the lane, and plotted against time. All dNTPs and ATP solutions had been pretreated with thermostable pyrophosphatase (100 μl of 64 mM nucleotide was incubated with 1 U of pyrophosphatase at 75°C for 10 min). Expression and purification of WT and mutant RT were described previously (21). Expression vectors for 41L, 215Y, 41L/215Y, and 67N/70R/215F/219Q RTs were derived from pKRT2 (8). Mutations were introduced by PCR using the megaprimer method (28). To construct an expression vector for 67N/70R/215Y/219Q RT, an RT sequence containing these mutations was transferred from the infectious proviral clone into pTRc99 (Pharmacia Biotech) using *Xba*I and *Xma*I sites introduced for that purpose (30). All constructs were modified to introduce an N-terminal hexahistidine extension on the expressed protein (21) and were confirmed by DNA sequence analysis.
TABLE 1. Apparent second-order rate constants for ATP-dependent removal of AZTMP and synthesis of Ap₄ddA by HIV-1 WT and mutant RTs

<table>
<thead>
<tr>
<th>HIV-1 RT</th>
<th>ATP-dependent removal of AZTMP (kcat/Km ATP)</th>
<th>Formation of Ap₄ddA (kcat/Km ATP)</th>
<th>Fold increase</th>
<th>Fold increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>0.066 ± 0.010 (M⁻¹ s⁻¹)</td>
<td>0.21 ± 0.04 (M⁻¹ s⁻¹)</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>67N/70R/215F/219Q</td>
<td>0.33 ± 0.01 (M⁻¹ s⁻¹)</td>
<td>0.83 ± 0.06 (M⁻¹ s⁻¹)</td>
<td>5.0idend</td>
<td>3.9idend</td>
</tr>
<tr>
<td>41L</td>
<td>0.11 ± 0.02 (M⁻¹ s⁻¹)</td>
<td>0.28 ± 0.01 (M⁻¹ s⁻¹)</td>
<td>1.7idend</td>
<td>1.3idend</td>
</tr>
<tr>
<td>215Y</td>
<td>0.15 ± 0.01 (M⁻¹ s⁻¹)</td>
<td>0.83 ± 0.06 (M⁻¹ s⁻¹)</td>
<td>2.3idend</td>
<td>3.9idend</td>
</tr>
<tr>
<td>41L/215Y</td>
<td>0.22 ± 0.03 (M⁻¹ s⁻¹)</td>
<td>1.9 ± 0.4 (M⁻¹ s⁻¹)</td>
<td>9.0idend</td>
<td>9.0idend</td>
</tr>
<tr>
<td>67N/70R/215Y/219Q</td>
<td>0.66 ± 0.13 (M⁻¹ s⁻¹)</td>
<td>3.3 ± 0.6 (M⁻¹ s⁻¹)</td>
<td>10idend</td>
<td>16idend</td>
</tr>
</tbody>
</table>

a Data obtained from experiments performed as described in the legend to Fig. 1D were fitted to hyperbolas to obtain kcat and Km ATP.

b Data from experiments performed as described in the legend to Fig. 2B were fitted to hyperbolas to obtain kcat and Km ATP.

c Values were derived from two to eight repeated determinations and are given as means ± standard deviation.

d Significantly different from the WT value (P < 0.05) by Student's t-test corrected for multiple comparisons.

e Not significantly different from the WT value (P > 0.05).

To measure removal of ddAMP, DNA primer L32 (5’-CT ACTAGTTTTCTCCATCTAGACGATACCAGA-3’) was annealed with DNA template WL50 and chain terminated by extending with [32P]ddATP as previously reported (19, 21). The [32P]ddAMP-terminated L32 primer-WL50 template was reisolated and incubated with excess WT or mutant RT in the presence of ATP. Products were separated by polyacrylamide gel electrophoresis, and 32P-labeled dinucleoside tetraphosphate (Ap₄ddA) was quantitated by phosphorimaging (Fig. 2C). As with AZTMP removal, the mutant enzymes had pyrophosphorylase activities that were at most equal to that of WT RT.

Specificity of the acceptor substrate used in dinucleoside polyphosphate synthesis. To define the role of the AZT resistance mutations in the primer unblocking reaction, we tested the effects of various nucleotide acceptor substrates on the efficiency of removal of ddAMP (Table 2). For WT RT there was little difference in the kcat/Km (specifcity constant) for dinucleoside polyphosphate synthesis using ATP, UTP, UDP, or methylated ATP or UTP as the substrate. In contrast, for the three mutant enzymes, the specificity constants for ATP were greater than for UTP, and the specificity constants for the methylated forms of ATP and UTP were greater than for the unmethylated nucleotides. Each enzyme used 5,6-dihydro-UTP less efficiently than UTP, and the differences between mutant and WT RT were smaller with dihydro-UTP. For example, kcat/Km for dinucleoside polyphosphate synthesis by 67N/70R/215Y/219Q RT was 7.4 times that of WT RT with UTP as the substrate but only 3.4 times that of WT RT with dihydro-UTP as the acceptor substrate. In agreement with a previous report (19), the mutant enzymes were similar to WT RT when UDP was used as the substrate.

Inhibition of primer rescue and dinucleoside polyphosphate synthesis by the next complementary dNTP. It was demonstrated previously (19, 20) that removal of chain terminators by HIV-1 RT is determined by at least two factors, the catalytic efficiency of mutant or WT RT to carry out the removal reaction and the sensitivity of that reaction to inhibition by the next complementary dNTP. Removal of ddAMP, d4TMP, and RT was increased 9-fold and that by 67N/70R/215Y/219Q RT was increased 16-fold over that by WT RT.

Similar methods were used to measure the pyrophosphorylation reaction catalyzed by WT and mutant enzymes. The [32P]ddAMP-terminated primer-template was incubated with WT or mutant RTs in the presence of PPi and 32P-labeled ddATP was quantitated by phosphorimaging (Fig. 2C). As with AZTMP removal, the mutant enzymes had pyrophosphorylase activities that were at most equal to that of WT RT.

FIG. 2. Effect of AZT resistance mutations on removal of [32P]ddAMP from blocked primer-template through transfer to ATP or PPi (A) [32P]ddAMP-terminated L32 primer–WL50 template (5 nM) was incubated with the indicated RT and 3.2 mM ATP for 5, 10, 20, or 40 min at 37°C. Products were separated on a 20% denaturing polyacrylamide gel (data not shown). The radioactivity in primer and Ap₄ddA was quantitated by phosphorimaging, and the percentage of label in ddATP was plotted against time.
ddTMP is inhibited by low concentrations of the next complementary dNTP, whereas removal of AZTMP is much less sensitive to this inhibition. Therefore, it was important to assess the sensitivity to dNTP inhibition for each mutant enzyme.

Rescue of AZTMP-terminated primer-template was measured as described above and inhibition by the next complementary dNTP (dGTP) was determined. The percent inhibition was plotted against dGTP concentration and fitted to a hyperbola to obtain the 50% inhibitory concentration (IC$_{50}$) for each enzyme (Table 3). Rescue by WT, 41L, 41L/215Y, and 41L/215Y/219Q RTs was slightly more sensitive to this inhibition. Therefore, it was important to assess the sensitivity to dNTP inhibition for each mutant enzyme.

To illustrate, the rate of in vitro removal of AZTMP at a single termination site by 67N/70R/215Y/219Q RT and 67N/70R/215Y/219Q RT and 67N/70R/215Y/219Q RT, but the differences were not significant.

We also measured inhibition of removal of ddAMP residues by TTP, the dNTP complementary to the next position on the primer-template, by quantitating the formation of [32P]Ap4ddA in the presence of various concentrations of TTP for each of the mutant enzymes (Table 3). As previously reported (19), removal of AZTMP was much less sensitive to inhibition by the next complementary dNTP than removal of ddAMP for all of the enzymes studied. Effects of the mutations were parallel for AZTMP removal and Ap4ddA synthesis. In summary, the 215Y and 67N/70R/215F/219Q enzymes show slightly reduced ability to interact with the next complementary dNTP, but the effect is too small to be convincing in these experiments.

Conclusions. The present studies show that the in vitro removal of AZTMP from the 3' termini of DNA chains by HIV-1 RT containing AZT resistance mutations is roughly proportional to the level of AZT resistance observed in cell culture assays for recombinant viruses containing the same mutations. To illustrate, the rate of in vitro removal of AZTMP at a single termination site by 67N/70R/215Y/219Q RT and 67N/70R/215F/219Q RT was 5 to 10 times that by the WT enzyme, whereas in vivo, in plaque reduction assays, HIV-1 containing these mutations was 120- to 150-fold less sensitive to AZT than WT HIV-1 (14). 41L/215Y RT catalyzed AZTMP removal at 3.3 times the rate of WT enzyme, compared with 64-fold AZT resistance of virus encoding 41L/215Y RT in cell culture (14). Mutant RT containing only the 215Y mutation removed AZTMP at a rate 2.3 times that of WT RT, compared with a 16-fold AZT resistance for virus containing this mutation (14). RT containing the M41L mutation alone exhibited a minimal increase in AZTMP removal, and the M41L mutant virus showed only fourfold AZT resistance (14). Since many factors contribute to the quantitative measurement of drug sensitivity in cells, the phenotypic assay results cannot be interpreted in terms of the number of AZTMP residues incorporated and removed in vivo; however, we have shown that the difference between mutant and WT enzyme is greater when multiple unblocking and termination events occur (19), and it is reasonable that an increase in removal of AZTMP at each site where termination occurs will be further amplified when replication of the entire viral genome is considered. Our results demonstrate a strong correlation between the in vitro and the in vivo effects of these mutations.

An indication of the role of these amino acid substitutions in the removal of chain terminators can be obtained from the molecular structures that have been reported for HIV-1 RT (11, 13, 15, 24, 26). Figure 3 shows the location of residues 41, 67, 70, 215, and 219 in WT RT in the structure of a covalently trapped catalytic complex reported by Huang et al. (11), which contains primer-template as well as the next complementary

### Table 2. Ability of WT and AZT-resistant RTs to use various nucleotides as substrate acceptors for removal of ddAMP from blocked primer-templates through dinucleoside polyphosphate synthesis

<table>
<thead>
<tr>
<th>HIV-1 RT</th>
<th>ATP</th>
<th>Me-ATP</th>
<th>UTP</th>
<th>Me-UTP</th>
<th>Dihydro-UTP</th>
<th>UDP</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>0.21 ± 0.04 (1.0)</td>
<td>0.22 ± 0.02 (1.0)</td>
<td>0.19 ± 0.01 (1.0)</td>
<td>0.17 ± 0.08 (1.0)</td>
<td>0.056 ± 0.008 (1.0)</td>
<td>0.32 ± 0.04 (1.0)</td>
</tr>
<tr>
<td>215Y</td>
<td>0.38 ± 0.06 (3.9)</td>
<td>1.3 ± 0.3 (5.9)</td>
<td>0.42 ± 0.10 (2.2)</td>
<td>0.39 ± 0.08 (3.5)</td>
<td>0.056 ± 0.003 (1.0)</td>
<td>0.23 ± 0.001 (0.7)</td>
</tr>
<tr>
<td>41L/215Y</td>
<td>1.9 ± 0.4 (9.0)</td>
<td>3.0 ± 1.1 (14)</td>
<td>0.55 ± 0.03 (2.9)</td>
<td>0.98 ± 0.26 (5.8)</td>
<td>0.10 ± 0.002 (1.8)</td>
<td>0.29 ± 0.01 (0.9)</td>
</tr>
<tr>
<td>67N/70R/215Y/219Q</td>
<td>3.3 ± 0.6 (16)</td>
<td>4.6 ± 2.3 (21)</td>
<td>1.4 ± 0.1 (7.4)</td>
<td>1.6 ± 0.6 (9.4)</td>
<td>0.19 ± 0.01 (3.4)</td>
<td>0.51 ± 0.01 (1.6)</td>
</tr>
</tbody>
</table>

*Experiments were performed as described in the legend to Fig. 2B with the indicated RT and nucleotide substrate. The rate of dinucleoside polyphosphate synthesis was plotted against nucleotide concentration and fitted to a hyperbola using SigmaPlot 4.0 to obtain the $k_{cat}$ and $K_m$. Data are the averages of two to eight experiments ± standard deviations. Numbers in parenthesis are increase (fold) versus the WT value. Significance of difference from WT was estimated by Student’s $t$ test for multiple comparisons. $N$-methyladenosine-5'-triphosphate (Me-ATP), 5-methyluridine-5'-triphosphate (Me-UTP), and dihydro-UTP were purchased from TriLink Biotechnologies, Inc. and treated with thermostable pyrophosphatase as described in the legend to Fig. 1, except dihydro-UTP, which was treated with inorganic pyrophosphatase (Roche Molecular Biochemicals) at 37°C to minimize breakdown to the diphosphate.

### Table 3. Ability of the next complementary dNTP to inhibit ATP-dependent primer rescue by WT and mutant RTs

<table>
<thead>
<tr>
<th>HIV-1 RT</th>
<th>IC$_{50}$ (µM) for next dNTP$^a$</th>
<th>AZTMP terminated primer-template$^b$</th>
<th>ddAMP terminated except as indicated$^c$</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>80 ± 13</td>
<td>4.0 ± 0.7</td>
<td></td>
</tr>
<tr>
<td>67N/70R/215F/219Q</td>
<td>149 ± 3</td>
<td>10.8 ± 1.9$^d$</td>
<td></td>
</tr>
<tr>
<td>41L</td>
<td>53 ± 3</td>
<td>3.2 ± 0.1</td>
<td></td>
</tr>
<tr>
<td>215Y</td>
<td>135 ± 25</td>
<td>8.3 ± 0.6$^d$</td>
<td></td>
</tr>
<tr>
<td>41L/215Y</td>
<td>85 ± 16</td>
<td>4.9 ± 2.3</td>
<td></td>
</tr>
<tr>
<td>67N/70R/215F/219Q</td>
<td>62 ± 2</td>
<td>6.6 ± 2.2</td>
<td></td>
</tr>
</tbody>
</table>

$^a$ The numbers were obtained from two to six experiments and are given as means ± standard deviations. By Student’s $t$ test, the difference from WT values was not significant for any of the mutant enzymes tested ($P > 0.05$) except as indicated.

$^b$ Primer rescue experiments were performed as described in the legend to Fig. 1A in the presence of dGTP. The percent inhibition of primer rescue was plotted against [dGTP], and the data were fitted to a hyperbola to obtain the IC$_{50}$. Primer rescue experiments were performed as described in the legend to Fig. 2A in the presence of TTP. The percent inhibition of primer rescue was plotted against [TTP], and the data were fitted to a hyperbola to obtain the IC$_{50}$.

$^c$ Ap$_{4x}$ddA synthesis experiments were performed as described in the legend to Fig. 2A in the presence of TTP. The percent inhibition of Ap$_{4x}$ddA synthesis was plotted against [TTP], and the data were fitted to a hyperbola to obtain the IC$_{50}$.

$^d$ $P < 0.05$.
dNTP, TTP. The complex is identical whether the bound TTP is considered the substrate for polymerization or the product of PP$_i$-dependent removal of TMP from the primer terminus. An analogous structure can be envisioned after ATP-dependent removal of TMP from the primer terminus. However, instead of TTP, the product is considered the substrate for polymerization or the product of ATP-dependent removal reaction through interactions with the adenine base derived from ATP. This hypothesis can induce long-range conformational changes in the enzyme, which should minimize the effects of differences in structure, and the α-phosphate and the adenosine moieties of ATP (not depicted in Fig. 3) would extend beyond the three phosphates of TTP in this structure.

The amino acids corresponding to codons 41, 67, 70, 215, and 219 in the WT enzyme are shown by space-filling models in Fig. 3. These residues identify a region on the surface of the protein just distal to the γ-phosphate of the bound TTP (Fig. 3, left panel). When the structure is viewed by looking down the phosphate chain of TTP (Fig. 3, right panel), these amino acids surround a position that would be occupied by an extension of the phosphate chain described in the previous paragraph. Their locations suggest that they may facilitate the ATP-dependent removal reaction through interactions with the adenosine and phosphate moieties in reaction intermediates. Introduction of either phenylalanine or tyrosine at codon 215 is crucial for AZT resistance (16, 17, 25), suggesting that resistance is facilitated by the introduction of an aromatic group in a position that could allow formation of π-π interactions with the adenine base derived from ATP. This hypothesis is strongly supported by the data in Table 2. ATP is a more efficient substrate than UTP when tested with the mutant enzymes, in agreement with the expectation that a purine base will form stronger π-π interactions than a pyrimidine base (27). Introduction of a methyl group on the aromatic base of either ATP or UTP increased the catalytic efficiency of the reaction by the mutant enzymes, and methylation has been shown to enhance π-π interactions (3, 27). Finally, reduction of a double bond in UTP to form dihydro-UTP preferentially reduced the catalytic efficiency of the mutant enzymes, in agreement with the loss of aromatic structure resulting from this modification, which would disfavor π-π interactions. The M41L and T215Y mutations interact to enhance resistance in vitro (14) and our results are also consistent with a cooperative interaction between these mutations in vivo. These residues are not close enough to each other for direct interaction, and simultaneous interaction with the adenosine moiety of the reaction intermediate also seems unlikely. The molecular basis of their functional interaction remains to be determined.

From the structural considerations described above, we would predict that the rate of removal of chain-terminators would not be increased in the mutant enzyme when PP$_i$ is used as the acceptor substrate, and our results agree with this prediction. By contrast, Arion et al. (1) reported that the rate of pyrophosphorolysis of AZTMP-terminated primers was increased for 67N/70R/215F/219Q and 67N/70R mutant RTs. Canard et al. (4) have reported that the 67N/70R/215F/219Q RT has enhanced affinity for AZTMP-terminated primer-template, and it is possible that increased pyrophosphorolysis reported by Arion et al. (1) reflects this difference, since limiting enzyme concentrations were used in their assays. Our experiments were carried out with a large excess of WT or mutant enzyme, which should minimize the effects of differences in affinity for primer-template.

Ren et al. (24) have shown that the 215F/219Q mutations can induce long-range conformational changes in the enzyme and these structural perturbations may affect the dNTP-binding site. Our results and those in reference 19 suggest that three mutant enzymes (215Y, 215F/219Q, and 67N/70R/215F/219Q RTs) have decreased sensitivity to inhibition of removal of ddAMP by the next complementary dNTP, implying that the
mutations facilitate the removal reaction both directly and indirectly. While the data suggest that dNTP binding is slightly impaired in these mutant enzymes, more direct assays may be needed to confirm this observation. Additional studies are also necessary to investigate the possible roles of other mutations associated with AZT resistance (including the 210W mutation and insertions at codon 69) in the removal reaction; however, the results in this report extend the previous conclusion (19) that enhanced nucleotide-dependent removal of AZTTP by AZT resistant RT plays an important role in the biochemical mechanism of AZT resistance.

We thank Hengemeh Bazmi at the University of Pittsburgh for providing us with the expression vector for 67N/70R/215Y/219Q RT and Arun Malhotra of the University of Miami for help with Fig. 3. This work was supported by NIH grants AI-39973 (W.A.S.) and DK-26206 (A.G.S.).

REFERENCES

Downloaded from http://aac.asm.org on September 21, 2017 by guest